Events & Presentations
Phase 3 Trial of Roluperidone (MIN-101) for Treatment of Negative Symptoms in Schizophrenia
Jun 5, 2020 at 8:30 AM EDT
Jun 5, 2020
8:30 AM EDT
8:30 AM EDT